Rak
0000358654
Donate
Active substances for the treatment of:

Malignant pancreatic cancer

Name of active substance (medicine) The European Society for Medical Oncology (ESMO). Published scientific research demonstrates that the observance of such scientific community guidelines has a positive impact on patient survival rates. Is it included in
the European standard  of treatment (according to ESMO)?
Access status (National Health Fund reimbursement) Additional information
Erlotinib The drug in this indication is not refunded No reimbursement Erlotinib in combination with gemcitabine is indicated for the treatment of patients with metastatic pancreatic cancer. When prescribing Tarceva, factors associated with prolonged survival should be taken into account. No survival advantage could be shown for patients with locally advanced disease. EPAR/SmPC
Nab-paclitaxel The drug in this indication is reimbursed for a narrower group of patients than is apparent from the ESMO guidelines Reimbursement with restrictions Nab-paclitaxel in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas. EPAR/SmPC Drug programme
Irinotecan hydrochloride trihydrate The drug in this indication is not refunded No reimbursement Treatment of metastatic adenocarcinoma of the pancreas, in combination with 5-fluorouracil (5-FU) and leucovorin (LV), in adult patients who have progressed following gemcitabine based therapy. EPAR/SmPC